Alpha Teknova, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 09, 2023 at 04:07 pm EST
Share
Alpha Teknova, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 8.17 million compared to USD 10.69 million a year ago. Net loss was USD 10.15 million compared to USD 22.47 million a year ago. Basic loss per share from continuing operations was USD 0.34 compared to USD 0.8 a year ago. Diluted loss per share from continuing operations was USD 0.34 compared to USD 0.8 a year ago.
For the nine months, sales was USD 28.82 million compared to USD 33.53 million a year ago. Net loss was USD 26.12 million compared to USD 34.17 million a year ago. Basic loss per share from continuing operations was USD 0.91 compared to USD 1.22 a year ago.
Alpha Teknova, Inc. is a producer of critical reagents for the research, discovery, development, and commercialization of therapies, vaccines, and molecular diagnostics. It offers two primary business lines, which include lab essentials and clinical solutions. It also offers three primary product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. The Company offers its liquid cell culture media and supplements and molecular biology reagents in both of its two product categories; pre-poured media plates are available in its Lab Essentials category only. Its customers include pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostics franchises, and academic and government research institutions developing vaccines and therapies and performing basic research.